16:45 - 15.10.2024
October 15, Fineko/abc.az. American company Johnson & Johnson reported a stronger-than-expected profit for the third quarter, which was driven by increased sales of cancer drug Darzalex.
ABC.AZ reports that Bloomberg writes about this.
Meanwhile, the company lowered its annual profit forecasts due to the acquisition of V-Wave Ltd. The company said it will pay up to $1.7 billion during the quarter for V-Wave, which is developing an implantable device for the treatment of heart failure.
According to J&J statement, adjusted earnings in the last quarter decreased by 9% yoy to $2.42 per share, surpassing Wall Street's estimate of $2.19 per share.
Total sales grew almost by 5.2% up to $22.5 bn, exceeding analysts' expectations more than by $400 million. At that, sales of myeloma drug Darzalex increased by over 20%.
